Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265766 | 1.00 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL5255020 | 1.00 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| Hydrochloric Acid SCHEMBL1003531 | 0.98 | USP2 (0.44) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL1913754 | 0.88 | HCRTR1 (0.44) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL8144693 | 0.78 | HTR2A (0.41) | USP2NPC1MEN1KMT2APOLB | |
| SCHEMBL24075123 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL10373039 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL12657420 | 0.75 | NPC1 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL7556064 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 | |
| SCHEMBL12651544 | 0.75 | USP2 (0.45) | USP2NPC1ALPLALPIMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-7094909-B2 | Reacting an amide compound containing hydroxy and a carboxyl group and having benzene ring, with a halogenated alkyl aminocarbonyl-pyrrolidine with 2-fluoro groups substituted at the ring carbon, by amindation of amine and carboxyl group | AGOURON PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1409466-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-0541168-B1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO INC (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5717097-A | N-(2(R)-HYDROXY-1(S)-INDANYL)-2(R)-PHENYLMETHYL-4(S)-(HYDROXY) -5-SUBSTITUTED-N'-(T-BUTYLCARBAMOYL)PIPERAZINYL))PENTANEAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5668132-A | HIV Protease inhibitors useful for the treatment of AIDS | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5527799-A | ADMINISTERING MIXTURE OF TWO COMPOUNDS AND OPTIONAL AZT | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0696277-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO. INC. (US) | 1996-02-14 | — | — | EP | disclosed |
| US-5413999-A | structure is piperazine containing amides | MERCK & CO., INC. (US) | 1995-05-09 | — | — | US | disclosed |
| WO-1994026717-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994022480-A1 | HIV PROTEASE INHIBITORS IN PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0617968-A1 | HIV protease inhibitors in pharmaceutical combinant for the treatment of AIDS | MERCK & CO. INC. (US) | 1994-10-05 | — | — | EP | disclosed |
| WO-1993009096-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | USP2 1237/4885NPC1 827/4885ALPL 584/4885 |
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | BACE1, BACE2, APBA1 | USP2 2307/4885NPC1 143/4885ALPL 3415/4885 |
| US-20040204591-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | FURIN, PREP, PRSS1 | USP2 2104/4885NPC1 178/4885ALPL 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.